Trial Profile
A Randomized, Phase II Study of Anlotinib Combined With Sintilimab(IBI 308) in First-generation EGFR-TKIs Drug Resistance Along With T790M Negative NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Sintilimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Dec 2018 New trial record